Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar-Apr;10(2):97-105.
doi: 10.4103/idoj.IDOJ_249_17.

Update on Management of Polycystic Ovarian Syndrome for Dermatologists

Shalini Gainder  1 , Bharti Sharma  1
Affiliations
Review

Update on Management of Polycystic Ovarian Syndrome for Dermatologists

Shalini Gainder et al. Indian Dermatol Online J. 2019 Mar-Apr.

Abstract

Polycystic ovarian syndrome (PCOS) is the commonest endocrine disorder in women having wide range of clinical manifestation. These women may present with reproductive, dermatological, metabolic, psychological, or neoplastic implications from adolescence to menopause. The common dermatological manifestations include hirsutism, acne, alopecia, or acanthosis nigricans. Women presenting with these dermatological manifestations must be evaluated for PCOS. A multidisciplinary team approach involving a reproductive endocrinologist, dermatologist, psychologist/psychiatrist, dietician, and sometimes a bariatric surgeon should be undertaken for long-term management of these patients. Unless metabolic and underlying endocrinal disturbances arecorrected and simultaneous life-style modification is adopted, cosmetic treatment would give only temporary relief.

Keywords: Acne; Polycystic ovarian syndrome; alopecia; antiandrogen drugs; hirsutism.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Etiopathogensis of PCOD
See this image and copyright information in PMC

References

    1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towardsa rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam G, editors. Polycystic Ovary Syndrome. Vol. 418. Boston: Blackwell Scientific; 1992. pp. 377–84.
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risksrelated to polycystic ovary syndrome (PCOS) Hum Reprod. 2004;19:41–7. - PubMed
    1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: Criteria for definingpolycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–45. - PubMed
    1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Societycriteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril. 2009;91:456–88. - PubMed
    1. National Institutes of Health: Evidence-based methodology workshop onpolycystic ovary syndrome, 2012. Executive summary